# EDGAR Filing Document

**Accession Number:** 0001022899
**File Stem:** 0001641172-25-024130
**Filing Date:** 2025-8
**Character Count:** 6585
**Document Hash:** 8dd0e31e7ad2713c479d769e87dc8920
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-024130.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001641172-25-024130

**CONFORMED SUBMISSION TYPE**: NT 10-Q

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**EFFECTIVENESS DATE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Protagenic Therapeutics, Inc.\new
- **CENTRAL INDEX KEY:** 0001022899
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 061390025
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12555
- **FILM NUMBER:** 251220580

**BUSINESS ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 994-8200

**MAIL ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Atrinsic, Inc.
- **DATE OF NAME CHANGE:** 20090630

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NEW MOTION, INC.
- **DATE OF NAME CHANGE:** 20070504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MPLC, Inc.
- **DATE OF NAME CHANGE:** 20050608

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

*(Check one):* ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐Form N-SAR ☐ Form N-CSR

For Period Ended: June 30, 2025

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

☐ Transition Report on Form N-SAR

For the Transition Period Ended:  

---

| |
|:---|
| *Read Instruction (on back page) Before Preparing Form. Please Print or Type.* |
| **Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.** |

---

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I - REGISTRANT INFORMATION**

<u>Protagenic Therapeutics, Inc.</u> <br> Full Name of Registrant

<u>Atrinsic, Inc.</u> <br> Former Name if Applicable

<u>149 Fifth Ave, Suite 500</u> <br> Address of Principal Executive Office *(Street and Number)*

<u>New York, NY 10010</u> <br> City, State and Zip Code

**PART II - RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

---

| | | |
|:---|:---|:---|
| ☒ | (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| ☒ | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| ☐ | (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

---

**PART III – NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Protagenic Therapeutics, Inc. (the "Company") will not be able to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 by the prescribed due date without unreasonable effort or expense.

On August 8, 2025, the Board of Directors approved a restructuring plan to transition to a virtual operating model and exit or modify certain obligations. To ensure complete and accurate reporting, management is finalizing the related accounting and disclosures, including:

&nbsp;&nbsp;&nbsp;&nbsp;1. Measuring and recording
 exit and disposal costs (e.g., severance and contract terminations) and determining the appropriate timing of recognition under applicable
 U.S. GAAP;

&nbsp;&nbsp;&nbsp;&nbsp;2. Classifying and presenting
 restructuring charges and related operating expenses; and

&nbsp;&nbsp;&nbsp;&nbsp;3. Updating "Subsequent
 Events," "Liquidity and Capital Resources," and related risk disclosures to reflect the plan and its expected cash
 flow impacts.

These procedures are being completed with Audit Committee oversight and consultation with the Company's external advisors.

The Company expects to file the Form 10-Q on or before August 19, 2025, within the five-day extension permitted by Rule 12b-25. The Company does not anticipate reporting a significant change in results of operations for the quarter ended June 30, 2025 as compared to the corresponding period in the prior year.

**PART IV - OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

<u>Alexander Arrow</u> <u>213</u> <u>260-4342</u> <br> (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ☐ No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Protagenic Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | PROTAGENIC THERAPEUTICS, INC. | PROTAGENIC THERAPEUTICS, INC. |
| Date: August 14, 2025 | By: | */s/ Alexander Arrow* |
|  | Name: | Alexander K. Arrow, MD |
|  | Title: | Chief Financial Officer |

---